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1. Introduction 
Stereotactic Radiosurgery (SRS) is a non-invasive technique for the delivery of highly 
focused ionizing radiation with extreme precision. It is used in neurosurgical practice as a 
less invasive means of targeting benign and malignant brain tumors, vascular 
malformations, and functional disorders. Its ability to elicit a desired response (e.g. tumor 
cell death) with minimal effect on normal surrounding structures is one of the many benefits 
that have led to more widespread use of stereotactic radiosurgical procedures in recent 
years. Current standard practice involves utilizing high resolution imaging for “stereotactic” 
3-dimensional (3-D) treatment planning under the guidance of a multidisciplinary team 
comprised of a neurosurgeon, radiation oncologist and medical physicist. To achieve the 
desired outcome, the SRS procedure can be performed in either a single treatment or in 
several applications (fractionated)1,2. 
2. Stereotactic radiosurgery: Brief history 
In 1951 neurosurgeon Lars Leksell developed the first stereotactic radiosurgery technique at 
Karolinska Hospital in Stockholm, Sweden. Dr. Leksell pioneered the stereotactic headframe 
for use in noninvasive lesioning in functional neurosurgery by attaching an orthovoltage x-
ray tube to a stereotactic frame in order to produce converging beams which would intersect 
at the treatment target1. In one of his first publications on the novel device he described how 
he could use the directed narrow beams of radiant energy in order to produce local 
destruction of undesirable brain tumor tissue. By adjusting the width of the beam to the size 
of the structure to be irradiated, and moving the beam guide transversely along the frame, 
the targeted radiation would meet at desired tissue site3.  
After finding his early work with the proton beam and linear accelerator radiosurgery 
overly cumbersome and inefficient, Dr. Leksell collaborated with Borge Larson in 1968 to 
design the first Gamma Knife device. This device contained 179 Cobalt 60 (Co-60) sources 
arranged symmetrically to irradiate a volume of brain tissue with a diameter of 
approximately 4, 8, or 14 mm1. The production and use of the Leksell Gamma Unit 
expanded in the late 1980s with the introduction of angiography, which enabled surgeons to 
delineate and therefore target arteriovenous malformations (AVMs). After getting the Food 
and Drug Administration (FDA) approval in 1982, the 201 Co-60 source gamma knife was 
used for the first time in the United States at the University of Pittsburgh, where it proved to 
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be a therapeutically effective and economical alternative to some conventional neurosurgery 
practices4.  
In recent years novel imaging techniques have been developed to optimize and expand the 
uses of the gamma knife and other stereotactic devices. Computer tomography (CT) and 
magnetic resonance imaging (MRI) techniques have improved the quality of the brain image 
and achieved a more precise localization of abnormalities and tumors in the brain. 
Combining these innovative imaging technologies with high-speed workstations that 
rapidly calculate and display 3-D dose distributions enables more effective and productive 
uses of these technologies1. In addition, positron emission tomography (PET) scans provide 
images that include metabolic data and functional data and in doing so add another layer of 
sophistication in the treatment of more complex targets such as rapidly proliferating tumors, 
including gliomas and metastases. The metabolic information provided by using PET scan 
imaging is complementary to anatomical information derived from CT or MRI imaging and 
assists in more precise identification of the target in dose-planning procedures5. 
3. Stereotactic radiosurgery technologies: Gamma Knife, LINAC, CyberKnife, 
Proton Beam 
3.1 Gamma Knife 
The Gamma Knife, developed by Leksell in 1968, has been reported to have been used in 
350,000 treatments by Leksell Society in 2005, at 237 centers6. It is made up of an 18,000 kg 
shield surrounding a hemispherical array of 201 sources of cobalt-60 with an average 
activity of 30 curie (Ci); as the cobalt-60 decays, the photons pass through various sized 
collimator holes in a helmet designed for the stereotactic procedure4. It has both fixed 
central and secondary beams on separate axes, with interchangeable outer collimator 
helmets that are used with respect to he lesion size—larger collimators are used for larger 
lesions, and smaller collimators for smaller diameter lesions4. The number of “shots” used to 
achieve the maximal target dose is dependent on the collimator size selected4. 
While Gamma Knife radiosurgery was originally designed to treat well-delineated lesions 
and targets, making it particularly useful for AVMs and benign tumors of the skull base, its 
uses have been expanded to include metastases, gliomas and other tumor types5. In addition 
to delineation of glial tumors, PET imaging technology has allowed for more accuracy in 
patients who have undergone previous surgery, which would otherwise make it difficult to 
define tumor recurrence accurately5. 
3.2 LINAC 
The development of linear accelerators (LINAC) allowed scientists and physicians to mimic 
the sharply defined small volumes of radiation produced by the Gamma Knife. Presently, 
LINAC systems utilized for SRS represent a predominant majority of the stereotactic 
systems worldwide. Such treatment applications have undergone a technical evolution. 
Early linear accelerators developed included the use of the Talairach stereotactic coordinate 
system with a 10-MV photon beam in 1983, and a 4-MV linear accelerator in 19851. Winston 
and Lutz later made use of the Brown-Roberts-Wells stereotactic frame with a floor stand in 
1986 to achieve mechanical accuracy of 0.5mm, an accuracy comparable to that of the 
Gamma Knife7.  In 1994 the FDA standardized commercial distribution of linear accelerator 
radiosurgery systems in the United States, and the expansion of such systems began1.  
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Fig. 1. Gamma Knife Perfexion Unit 
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Fig. 2. LINAC Treatment Planning 
The LINAC systems employ accelerated photons, much like the Gamma Knife system but 
rely on a different software and hardware than the Gamma Knife. It can be used with a 
frame or as a frameless system, and it has the advantage of being used for fractionated 
stereotactic radiotherapy which is for the most part not possible with Gamma Knife1.   
3.3 CyberKnife 
The CyberKnife has been developed in recent years as a frameless, robotic, image-guided 
stereotactic radiosurgery system that manipulates an X-band linear accelerator8. This recent 
adaptation allows for a more flexible treatment both in terms of the ability to deliver the 
therapy without using a frame (making the experience more comfortable for the patient), 
increasing fractionation flexibility, as well as increasing the ability to treat extracranial 
lesions8. The CyberKnife radiosurgery system computes the dose range and quantity by 
using data from the robot and camera image tracking system software, along with 
contributions from the assembled team’s treatment planning, based on CT imaging8.  
The CyberKnife enables facile stereotactic fractionation, eases patient discomfort due to lack 
of stereotactic frame, and does not require anesthesia in pediatric patients which is 
necessary with frame-based systems8. Additional applications of frameless radiosurgical 
methods include use in other organ systems and locations such as the spinal column, the 
mediastinum, pelvis and the retroperitoneal space8. 
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Fig. 3. CyberKnife Unit  
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3.4 Proton Beam 
The proton beam is a significantly more costly and far less frequently used stereotactic 
system than the above-described applications. Due to its prohibitively high cost and special 
shielding, proton beam facilities are very few in the United States or worldwide. Proton 
beam SRS relies on generating a charged particle. Charged particle intracranial SRS was first 
implemented in the 1950s and 1960s when Tobias et al began to irradiate brain tumors in 
1956 with high-energy, positively charged particles with a synchroclyclotron9. It was later 
used to treat intracranial lesions such as AVMs and pituitary adenomas1. Raju has estimated 
that a total of 6,500 patients had been treated with intracranial SRS using charged particle 
beams by 199510. The beam generated can manipulate the Bragg’s peak to adjust to the size 
of the tumor. The particular characteristics of proton radiation is a very low entry dose and a 
very sharp fall off dose past the Bragg peak, i.e., past the tumor. Such beam properties 
render proton beam application in the brain most useful for the lesions near critical 
structures which may produce untoward permanent damage if not spared - the optic chiasm 
or a brain stem - and/or special pathologies requiring very high doses of radiation (e.g., 
chordoma, chondrosarcoma).  
4. Indications for stereotactic radiosurgery 
While the first Gamma Unit using Co-60 was installed in the Sophiahemmet Hospital in 
Sweden in 1968 and was primarily intended for neurosurgery in deep fiber tracts or nuclei8, 
its expansion to other hospitals both in Sweden and abroad allowed it to evolve in its 
function and use, as its capabilities were questioned and expanded. Indications for current 
use of stereotactic radiosurgery are multifarious, and includes certain malignant or benign 
tumors that meet the criteria for radiosurgical treatment as well as AVMs11. Radiosurgery is 
an especially attractive therapeutic option for brain metastases because it can be used to 
treat small lesions that would be otherwise inaccessible with invasive surgery due to 
sensitive adjacent critical structures. It presents an especially attractive alternative option to 
invasive surgery for patients with co-morbidities11. Radiosurgery continues to be constantly 
evaluated for its benefits, risks, and effectiveness in comparison to standard surgical, 
radiation and pharmacological options.  
In addition to these more common uses, stereotactic radiosurgery is also used in a smaller 
percentage of cases for its original purpose—the treatment of functional disorders such 
movement disorders or intractable pain12. Of these functional SRS cases, the most common 
indication is trigeminal neuralgia, but experimental procedures for epilepsy and other 
psychiatric illness are also conducted in several centers under strict protocol. Ventrolateral 
thalamotomy is being studied as a possible radiosurgical treatment of tremor in patients 
with Parkinson disease or multiple sclerosis, as well as for treatment of essential tremor. A 
study by Friehs has shown success rates that are comparable to other treatments in older 
groups of patients13.  
5. Patient selection and preparation 
Selecting patients for stereotactic radiosurgery involves a comprehensive account and 
balance of the benefits and risks of the procedure, in relation to the history of the disease, 
the condition of the patient, and other alternative therapies14. This includes thorough 
consideration of the demographic and medical profile of the patient as well as the nature, 
size, shape, and location of the lesion. Such assessment requires the expertise of several 
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medical professionals including neurodiagnosticians, neurosurgeons, radiationoncologists, 
and medical physicians14. Each of these medical practitioners is trained to contribute and 
collaborate to the procedure according to their capabilities.  
Considerations with respect to the specifications of the tumor play a critical role both in 
deciding whether stereotactic radiosurgery is the appropriate treatment, and if so, how to 
approach the treatment. Radiosurgery is most often used to treat relatively small, well-
circumscribed tumors or vascular malformations less than 35 mm in diameter14,15. Patients 
with larger legions are usually poor candidates. This is due to the delayed radiation-related 
complications from the gradual as opposed to steep fall-off of large doses of radiation as 
well as other adverse symptoms related to mass effect15. Both of these complications lead to 
the destruction of surrounding tissues. As a result, a neurosurgical approach is likely 
required for patients with larger lesions, as opposed to a radiosurgical one. In addition to 
the size of the lesion, the location of adjacent neural structures, such as the optic chiasm, 
must be considered in treatment planning as these structures often make it difficult or 
impossible to access the target site13. 
In terms of patient demographic, the selection of radiosurgery as opposed to other modes of 
treatment also involves the assessment of patient preference, the neurological hazards of 
open surgical resection with general anesthesia for a particular patient, and the efficacy of 
alternative radiation techniques14. Considerations such as mental and physical patient 
motivation and cooperation (whether they are claustrophobic or are physically able to lie 
flat and still for the designated amount of time of the procedure) are important in 
determining whether radiosurgery is the optimal choice for the patient. . It is preferable that 
a candidate for SRS has a Karnofsky Permonance Status (KPS) >70. 
5.1 Patient preparation and frame application 
Stereotactic radiosurgery is most often an outpatient single day procedure. After the patient 
is determined to be a good candidate for this treatment and a date has been selected, pre-
operative measures must be undertaken to explain the procedure to the patient and they 
must also sign a form of consent. It is important that the patient understands that they will 
be required to lie flat and still for a prolonged period of time. Diuretics to prevent edema 
and anticonvulsants to prevent seizures during the procedure can be administered to the 
patient two weeks before the procedure.  
Administration of a mild oral sedative and local anesthetic are essential for gamma-knife 
radiosurgery because the treatment requires rigid fixation of the patient’s head in a metal 
head frame, which would otherwise cause discomfort. After the sedative and anesthesia is 
administered and allowed to take effect, the frame is then applied. Optimal frame placement 
is critical for frame-based radiosurgery as the placement of the frame must be precise in 
order to avoid cranial defects. Targets must be placed in the center of the frame so that the 
beams of radiation will meet properly at the planning target volume (PTV).  
Accurate placement of the frame requires comprehensive imaging and treatment planning 
by the radiosurgical team. Essential to the placement of the frame is defining the intracranial 
targets in stereotactic space16. This is done with various combinations of cerebral 
angiography, CT scan and MRI technologies both before the procedure and then again once 
the frame has been applied, with the latter set of coordinates specifying the PTV coordinates 
in relationship to the frame4. Stereotactic localization defines the coordinates of the volume 
of interest within the brain in terms of the external coordinates of the frame in order to align 
with the radiosurgical unit16. A fusion of the CT scan and an MRI provides a special 
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orientation of the target with respect to the stereotactic coordinates. The imaging data is 
analyzed by dose planning system software and the radiosurgical team. In recent years, 
advanced technologies such as positron emission tomography (PET) have been developed 
and implemented as previously mentioned, which enable the possibility of more accurate 
determination of PTV location in complicated cases. Examples of PET uses include glial 
tumors which are difficult to delineate from the surrounding tissue without additional 
metabolic data, which differentiates malignant tumor tissue based on its proliferation, as 
evidenced by the uptake of the radiolabeled glucose (18F)5. 
5.2 Imaging and treatment planning 
Because the dosage planning for stereotactic radiosurgery is done for the most part by 
computer software, data including the rectilinear (x, y, z) coordinates of the target, head 
configuration measurements and treatment angle data must be gathered in order for the 
appropriate dose to be localized to the target area4. Stereotaxis relates the patient to a 
mathematic coordinate system by using the head frame’s ring as a template on which the 
coordinate system can be applied17. A fiducial system attaches to the frame with imaging 
elements appropriate to the image modality used for treatment planning, and the data 
collected is inputted into a computer dose-planning system to create a stereotactic space15. In 
this way the treatment planning system identifies the coordinates of the target tissue and 
will administer the appropriate dosage only to that specific region.  
The software used to calculate the appropriate isodose must take into account the 
summated isodose curves that show the cumulative effect of beam isocenter placements, 
collimator size, beam weighing and head angulation15. The system also calculates the 
amount of radiation that non-PTV structures are exposed to, allowing the treatment team to 
adjust the plan in order to minimize the effect on these surrounding structures. It is 
important that the software recognizes incorrect or dangerous treatment, and that the 
delivery system is contained in a room that protects treatment personnel as well as the 
public from harmful radiation15.  
Dosimetric evaluation by the clinical team often includes both qualitative and quantitative 
histograms, including isodose surface displays and integral dose-volume histograms18. 
Computing the appropriate dose makes up a majority of the time of the planning procedure 
as it requires computational algorithms in addition to clinical input in order to optimize the 
treatment. In computing the isocenter, small movements can alter the minimum surface 
dose by as much as 30%18.  
6. Selected clinical brain tumor applications of stereotactic radiosurgery 
The clinical applications of stereotactic radiosurgery are numerous and include acoustic 
neuroma, meningioma, brain metastases, pituitary adenoma, glioblastoma multiforme, 
craniopharyngioma, trigeminal and other cranial nerve schwannoma, glomus jugulare 
tumors, hemangiopericytomas, ependymomas, and recurrent medulloblastoma. The 
following section will describe the specific indications for a number of these tumor types as 
well as the outcomes as examined by various studies. To improve treatment of many of 
these tumor types further research must be done in order to understand and optimize the 
benefits and detriments of different procedures. Contradictory data has been presented both 
within studies and between studies in choosing between a surgical, radiosurgical or 
radiation approach to tumor treatment planning. 
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6.1 Vestibular schwannoma / acoustic neuroma 
Ideal active management for small-to-medium-sized vestibular schwannomas is still 
disputed and unclear, as a recent study by Pollock favored the radiosurgical over 
microsurgical approach, while Di Maio and Akagami showed no difference between groups 
of patients that were treated microsurgically, radiosurgically, or untreated with 
observation19,20,21. These studies were measured based on quality of life outcomes (QOL).  
Nonetheless, stereotactic surgery is presently used to treat vestibular schwannomas with 
favorable disease stabilization rates upwards of 90% with some studies showing tumor 
control rates up to 97%22,23. While rates of tumor control are comparable to those of 
conventional microsurgery, both treatments demonstrate a preservation of hearing as well 
of other quality of life effects that are far from optimal. Facial weakness and facial numbness 
due to trigeminal and facial nerve damage during resection or radiosurgical treatment of 
vestibular schwannomas have presented additional challenges to current practice, but occur 
at a low frequency (<3%)22. The preservation of cochlear nerve function poses the 
predominant challenge to the surgical approach as well as the radiosurgical approach with a 
resultant preservation of useful hearing between 33-50% for small-to-medium-sized tumors, 
and considerably lower for larger tumors22. 
A fractionated approach has been investigated in the attempt to preserve hearing and 
minimize incidental cranial nerve injury22. Poen’s study of 33 patients with vestibular 
schwannoma demonstrated that a 24 hour three-fraction approach allows for a preservation 
of useful hearing (Gardner-Robertson Class 1-2) in 77% of patients two years after the 
treatment procedure22. The fractionated SRS protocol that was designed incorporated the 
physical advantages of rigid stereotactic localization, the practicality of a 1-day treatment, 
and the potential biological advantages of an abbreviated fractionation schedule22. It also 
takes advantage of the radiobiological principles that predict that fractionated radiotherapy 
will allow for repair of sublethal damage in normal tissues, reoxygenation of hypoxic tumor 
cells and redistribution of surviving tumor cells into a more radiosensitive cell cycle phase 
that is more susceptible to further radiation22.  
While facial weakness and numbness is less common than hearing loss in the treatment of 
vestibular schwannomas, a review study by Yang has demonstrated that up to 3.8% of 
patients treated with Gamma Knife radiosurgery for vestibular schwannomas have poor to 
no facial nerve preservation after surgery24. As a result, facial nerve preservation is still a 
great concern of patients undergoing radiosurgery for vestibular schwannomas. Treatment 
with radiation less than 13 Gy has been shown to have better facial nerve preservation rates 
after Gamma Knife radiosurgery for vestibular schwannoma (≤13 Gy = 98.5% vs. ≥13 Gy = 
94.7%, P<0.0001)24. 
6.2 Stereotactic radiosurgery for meningiomas 
Stereotactic radiosurgery is presently an alternative or adjuvant approach alongside surgical 
resection for treatment and management of intracranial meningiomas. Radiosurgery 
presents a favorable approach to microsurgery in patients with residual or recurrent small 
volume tumors who have had previous resection, those with high risk symptomatic primary 
tumors, as well as in patients with medical illness or advanced age25. It is not recommended 
for optic sheath tumors in patients with preserved vision 25. A study by Konziolka examined 
the rate of tumor growth control in 972 patients with 1045 intracranial meningiomas and 
found the control rate to be 93% in patients with benign meningiomas and low concurrent 
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risks25. In this study a mean of 7.5 isocenters were used to provide conformal radiosurgery, 
with a mean dose to tumor margin at 14 Gy and mean maximum delivered dose of 28 Gy25. 
Overall morbidity rate was 7.7% in patients who underwent stereotactic radiosurgical 
treatment for intracranial meningiomas at an average time of 11 months, and symptomatic 
peritumoral imaging changes were present in 4% of patients at 8 months25. 
In another study by Lee of the long-term outcomes in 176 patients who had undergone 
stereotactic radiosurgery for cavernous sinus meningiomas, neurological status improved in 
46 patients (29%), was stabilized in 99 (62%), and worsened in 14 (9%)26. While 
microsurgical approach to skull base has become more feasible in present years to achieve 
rates of 22.9-100% due to technique developments, complete resection still has the likely 
possibility of resultant disease and death while the alternative, incomplete resection, usually 
fails to arrest tumor progression26. With a radiosurgical approach in treating cavernus sinus 
meningiomas, tumor volume was shown to decrease in 54 patients (34%), was stabilized in 
96 (60%), and increased in nine (6%)26. By placing the 50% or greater isodose at the irregular 
tumor margin, three-dimensional conformation radiosurgery was achieved with a median 
maximum dose of 26 Gy, and median dose delivered to margin at 13 Gy26. Adverse effects of 
radiation occurred in 6.7% of patients where clinical or neurological deterioration occurred 
despite lack of tumor growth including visual deterioration, trigemnial nerve dysfunction 
and partial complex seizures26. 
Overall, multiple isocenter stereotactic radiosurgery allows for focused irradiation of 
irregular meningioma tumor margins and volumes, and prevents adjacent critical structures 
from injury in comparison to microsurgical techniques. Stereotactic radiosurgery is often 
recommended for smaller tumors, as large tumors respond poorly to due to mass effect 25,26. 
Several studies have analyzed various types of intracranial meningiomas and demonstrated 
that tumor recurrence or progression is statistically similar in both patients who have 
undergone resection and those who have been treated radiosurgically, with low morbidity 
in small- to-moderate-sized meningiomas without the risks associated with invasive 
surgery27,28. 
6.3 Stereotactic radiosurgery for brain metastases 
Stereotactic radiosurgery is currently being used to treat newly diagnosed metastatic 
tumors, recurrent brain metastases after previous whole brain radiation therapy (WBRT), 
and as a “boost” after WBRT. Brain metastases are the most common adult brain tumor, 
affecting 100,000-170,000 people annually in the United States29. Metastatic brain tumors 
have high incidence and follow a rapidly progressive course, requiring complex 
management which includes a combination of surgery, radiation and radiosurgery30. Even 
with the multimodal treatment, low median survival rates of around 6 months after WBRT 
persist, and these low survival rates have historically led the oncology community to desist 
from aggressive treatment of these tumors30.  
Stereotactic radiosurgery presents a non-invasive, less aggressive approach to depress the 
rate of growth in solitary brain metastases. Solitary metastases are especially good targets 
for radiosurgical treatment when they are caught in earlier stages by MRI surveillance at 
less than 3.5 cm, because they are usually spherical, discrete and contrast enhancing, 
allowing for accurate lesion delineation30. In addition, most metastases are uniformly 
sensitive to single fraction radiotherapy30.  
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For multiple brain metastases, treatment becomes less effective as the number of tumors 
increases. A study by Pollock demonstrated that the probability of tumor control after 
surgery and WBRT or radiosurgery decreases from 64% for one intracranial metastasis, to 
51% for two tumors, and to 41% for three<sup>31</sup>. Patients with fewer than four 
small- or medium-sized tumors can respond favorably to stereotactic radiosurgery32. 
Hypofractionated radiosurgery is the preferred option for patients that are poor surgical 
candidates due to co-morbidities or advanced systemic disease and it can be combined with 
resection for treatment of larger tumors32. In general, algorithms are followed to treat brain 
metastases through multimodal techniques that combine resection, WBRT and radiosurgery 
in attempt to maximize survival rates. 
7. Stereotactic radiosurgery for brain tumors: Risks and benefits 
7.1 Risks 
The risks associated with stereotactic radiosurgery can be categorized by the time of their 
presentation and are determined by various factors including tumor type, size, location, 
prior radiation and the radiation dose given.  
In a study by Warnick, complications were analyzed and categorized temporally. Acute 
complications occurring in the first seven days after radiosurgical treatment were rare and 
included nausea in 2-11% of patients within the first 24 hours, which was controlled with 
anti-emetics30. Edema was reported in 2-6% of patients, with improvement seen with 
corticosteroids administered pre-operatively in tumors more frequently associated with this 
complication30. Seizures were reported in 2-6% of patients within 24 hours, with greater 
occurrence in patients with pre-existing seizures and tumors near epileptogenic areas33.  
Subacute complications occurring within six months of the procedure, included uncommon 
occurrences of alopecia in 6% of patients, and the 'flare' phenomenon that presents as 
increased lesion volume, contrast enhancement and edema, resolving itself 9-12 months 
after the procedure30. Flare is a result of accumulation of necrotic tumor tissue. Chronic 
complications, referring to those persisting for longer than six months after the procedure, 
include radiation necrosis, which is the most severe of such side effects and is dependent on 
the diameter of the tumor diameter being radiated. To reduce the risk of late radiation 
effects on surrounding structures, WBRT is increasingly being omitted from the initial 
management strategy of brain metastases<sup>34,35</sup>. Finally, radiation-induced 
secondary neoplasms have been reported infrequently in few case studies. 
7.2 Potential benefits 
The potential benefits of stereotactic radiosurgery are extensive, making it an attractive 
alternative or even replacement treatment for tumor resection. It is a safe, effective, and non-
invasive procedure, and as a result is well tolerated in older patients as well as those with 
concurrent disease. It also allows most patients to return immediately to normal activities. 
Single or few treatments can produce a sustained effect in a wide variety of tumors, and 
multiple small tumors can be treated simultaneously while avoiding the systemic toxicity 
that accompanies pharmacological treatment. In addition, radiosurgery can be combined 
with other therapies for comprehensive, patient-specific treatment. As a result, stereotactic 
radiosurgery is being increasingly utilized tool in the treatment of brain tumors and its 
applications are bound to grow and develop in future years.  
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